跳至主要内容
临床试验/ISRCTN14633165
ISRCTN14633165已完成未知

Efficacy and safety of electrochemotherapy in basal cell carcinoma: A single-arm observational cohort study

Veneto Institute of Oncology IOv-IRCCS0 个研究点目标入组 84 人开始时间: 2017年3月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
84

研究概览

简要总结

2017 results in https://pubmed.ncbi.nlm.nih.gov/28569161/ (added 26/11/2020)

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Aged 18 years or older
  • 2. Cutaneous / subcutaneous histologically confirmed skin metastases or primary or recurrent basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)
  • 3. Measurable disease
  • 4. Unresponsive or unsuitable for conventional treatments
  • 5. In case of local BCC, the patients have to present with =2 tumors when located in the face or with =3 tumors when located in other anatomical regions
  • 6. Patients with laBCC had at least one lesion >2 cm or any size plus ?2 risk features so that surgical resection was deemed inappropriate; moreover, laBCC have to be previously irradiated or, alternatively, radiation therapy have to be considered contraindicated or inappropriate (e.g. multifocal disease)
  • 7. All subject have to be discussed in the frame of a multidisciplinary team
  • 8. Tumor size smaller than 3 cm in thickness
  • 9. Tumor not deeper than 3 cm
  • 10. No concomitant treatments one month before and two months following ECT
  • 11. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
  • 12. Life expectancy of at least three months
  • 13. Normal hematologic, hepatic and renal function

排除标准

  • 1. Abnormal respiratory function
  • 2. A cardiac pacemaker or arrhythmias
  • 3. Previous maximal exposure to bleomycin
  • 4. History of seizures

研究者

发起方
Veneto Institute of Oncology IOv-IRCCS

相似试验